A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases

Clinical Cancer Research

Volumn 16, Issue 21, 2010, Pages 5277-5287

  Kimball, Kristopher J ^a   Preuss, Meredith A ^a   Barnes, Mack N ^a   Wang, Minghui ^a   Siegal, Gene P ^a   Wan, Wen ^a   Kuo, Huichien ^a   Saddekni, Souheil ^a   Stockard, Cecil R ^a   Grizzle, William E ^a   Harris, Raymond D ^b   Aurigemma, Rosemarie ^b   Curiel, David T ^a   Alvarez, Ronald D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CONDITIONALLY REPLICATING ADENOVIRUS; DETA24 ARGINYLGLYCYLASPARTIC ACID; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALLERGY; ANTIBODY RESPONSE; ARTICLE; BLOOD DISEASE; BONE MARROW DISEASE; CANCER GROWTH; CANCER PAIN; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DRUG EFFICACY; FATIGUE; GASTROINTESTINAL DISEASE; GYNECOLOGIC CANCER; HEART ARRHYTHMIA; HUMAN; INFECTION; KIDNEY DISEASE; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAXIMUM TOLERATED DOSE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SKIN DISEASE; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; VIRUS REPLICATION; VIRUS SHEDDING;

ADENOVIRIDAE; AGED; AGED, 80 AND OVER; CANCER VACCINES; CARCINOMA; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; OLIGOPEPTIDES; ONCOLYTIC VIROTHERAPY; ORGANISMS, GENETICALLY MODIFIED; RECURRENCE; TUMOR CELLS, CULTURED; VACCINES, DNA; VIRAL TROPISM; VIRUS REPLICATION;

EID: 78049468477     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0791     Document Type: Article

References (29)

1. Brinton LA, Lacey JV, Sherman ME. Epidemiology of gynecologic cancers. In: Hoskins WJ, Perez CJ, Young RC, et al, editors. Principles and practice of gynecologic oncology. 4th ed Philadelphia (PA): Lippincott-Raven; 2005, p. 3-32.
2. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract 2007;4:101-17.
3. Kimball KJ, Numnum TM, Rocconi RP, Alvarez RD. Gene therapy for ovarian cancer. Curr Oncol Rep 2006;6:441-7.
4. Alemany R, Balague C, Curiel D. Replicative adenovirus for cancer therapy. Nat Biotechnol 2000;18:723-7.
5. Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 2006;32:875-86.
6. Niederacher D, Yan HY, An HX, Bender HG, Beckman MW. CDKN2 gene inactivation in epithelial sporadic ovarian cancer. Br J Cancer 1999;80:1920-6.
7. Vasey PA, Schulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1-55kd-gene deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-9.
8. Neumunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility, and biological activity. Gene Ther 2001;8:746-59.
9. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependant on tumor expression of primary Ad receptors. Ca Res 2001;61:813-7.
10. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. Virol 1999;72:9706-13.
11. Vanderkwaak T, Wang M, Navarro J, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999;74:227-34.
12. Bauerschmitz G, Lam J, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. CA Res 2002;62:1266-9.
13. Page JG, Tian B, Schweikart K, et al. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 2007;196:389e1-10.
14. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002;8:3348-59.
15. Ponnusamy MP, Venkatraman G, Singh AP, et al. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett 2007;251:247-57.
16. Schenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein LC. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007;9:910-21.
17. Kawahira H, Matsushita K, Shiratori T, et al. Viral shedding after p53 adenoviral gene therapy in 10 cases of esophageal cancer. Cancer Sci 2010;101:289-91.
18. Alvarez RD, Barnes MN, Gomez-Navarro J, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Can Res 2000;6:3081-7.
19. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002;1575:1-14.
20. Blackwell J, Li H, Navarro J, et al. Circumventing inhibitory factors in ascites fluid using a tropism modified adenoviral vector. Hum Gene Ther 2000;11:1657-69.
21. Galanis E, Hartmann LC, Cliby WA, et al. Phase I trial of intraperitoneal administration of an engineered strain of measles virus, modified to express carcinoembryonic antigen for recurrent ovarian cancer. Can Res 2010;70:875-82.
22. Hemminki A, Belousova N, Zinn K, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 2001;4:223-31.
23. Opyrchal M, Aderca I, Galanis E. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol 2009;542:705-17.
24. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009;16:473-88.
25. Rocconi RP, Zhu ZB, Stoff-Khalili M, et al. Gynecol Oncol 2007;105:113-21.
26. Kimball KJ, Rivera AA, Zinn KR, et al. Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer. Mol Imaging 2009;8:264-77.
27. Bauerschmitz GJ, Guse K, Kanerva A, et al. Triple-targeted oncolytic adenoviruses featuring the Cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006;14:164-74.
28. Stoff-Khalili MA, Rivera AA, Glascow JN, et al. A human adenoviral vector with a chimeric fiber from a canine adenovirus type 1 results in novel expanded tropism for cancer therapy. Gene Ther 2005;12:1696-706.
29. Yong RL, Shinojima N, Fueyo J, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 2009;69:8932-40.